

NEUROLOGIX INC/DE  
Form 8-K  
October 24, 2006

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

### CURRENT REPORT

### PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 24, 2006

Neurologix, Inc.

(Exact name of registrant as specified in its charter)

DELAWARE  
(State or other jurisdiction of  
incorporation or organization)

0-13347  
(Commission  
File Number)

06-1582875  
(I.R.S. Employer  
Identification No.)

ONE BRIDGE PLAZA, FORT LEE, NEW JERSEY  
(Address of principal executive offices)

07024  
(Zip Code)

(201) 592-6451  
(Registrant's telephone number,  
including area code)

None  
(Former name, former address and former fiscal year,  
if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

## Edgar Filing: NEUROLOGIX INC/DE - Form 8-K

- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13(e)-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01 Regulation of FD Disclosure**

On October 24, 2006, Neurologix, Inc. issued a press release announcing that John E. Mordock, its President and Chief Executive Officer, will make a presentation at the C.E. Untenberg, Towbin Life Sciences Conference to be held from October 30 - 31, 2006 in New York, New York. The press release is filed herewith as Exhibit 99.1.

The information, including the exhibit attached hereto, in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release issued on October 24, 2006

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEUROLOGIX, INC.

Date: October 24, 2006

By: /s/ Marc L. Panoff  
Marc L. Panoff  
Chief Financial Officer, Secretary and Treasurer

EXHIBITS

99.1 Press release, dated October 24, 2006